Functional avidity directs T-cell fate in autoreactive CD4+ T cells

Blood

Volumn 106, Issue 8, 2005, Pages 2798-2805

  Mallone, Roberto ^b   Kochik, Sharon A ^b   Reijonen, Helena ^b   Carson, Bryan ^b   Ziegler, Steven F ^b   Kwok, William W ^b   Nepom, Gerald T ^a  

^a BENAROYA RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

AGED; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CASE REPORT; CELL ACTIVATION; CELL FATE; CELL SURVIVAL; DENDRITIC CELL; HUMAN; HUMAN CELL; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE FUNCTION; MAJOR HISTOCOMPATIBILITY COMPLEX; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; STAINING; T LYMPHOCYTE;

EID: 27144469301     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2004-12-4848     Document Type: Article

References (55)

1. Verge C, Gianani R, Kawasaki E, et al. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes. 1996;45:926-933.
2. Roep BO. The role of T-cells in the pathogenesis of type 1 diabetes: from cause to cure. Diabetologia. 2003;46:305-321.
3. Reijonen H, Novak EJ, Kochik S, et al. Detection of GAD65-specific T-cells by major histocompatibility complex class II tetramers in type 1 diabetic patients and at-risk subjects. Diabetes. 2002;51:1375-1382.
4. Mallone R, Kochik SA, Laughlin EM, et al. Differential recognition and activation thresholds in human autoreactive GAD-specific T-cells. Diabetes. 2004;53:971-977.
5. Masteller EL, Bluestone JA. Immunotherapy of insulin-dependent diabetes mellitus. Curr Opin Immunol. 2002;14:652-659.
6. Mallone R, Nepom GT. Targeting T lymphocytes for immune monitoring and intervention in autoimmune diabetes. Am J Ther. 2005; In press.
7. Sharma SD, Nag B, Su XM, et al. Antigen-specific therapy of experimental allergic encephalomyelitis by soluble class II major histocompatibility complex-peptide complexes. Proc Natl Acad Sci U S A. 1991;88:11465-11469.
8. Spack EG, McCutcheon M, Corbelletta N, et al. Induction of tolerance in experimental autoimmune myasthenia gravis with solubilized MHC class II:acetylcholine receptor peptide complexes. J Autoimmun. 1995;8:787-807.
9. + T cells by a soluble dimeric peptide-MHC class II chimera. Nat Immunol. 2002;3:383-391.
10. Masteller EL, Warner MR, Ferlin W, et al. Peptide-MHC class II dimers as therapeutics to modulate antigen-specific T cell responses in autoimmune diabetes. J Immunol. 2003;171:5587-5595.
11. Casares S, Zong CS, Radu DL, et al. Antigen-specific signaling by a soluble, dimeric peptide/major histocompatibility complex class II/Fc chimera leading to T helper cell type 2 differentiation. J Exp Med. 1999;190:543-553.
12. Fahmy TM, Bieler JG, Edidin M, Schneck JP. Increased TCR avidity after T cell activation: a mechanism for sensing low-density antigen. Immunity. 2001;14:135-143.
13. Stefanova I, Hemmer B, Vergelli M, et al. TCR ligand discrimination is enforced by competing ERK positive and SHP-1 negative feedback pathways. Nat Immunol. 2003;4:248-254.
14. Tian J, Gregori S, Adorini L, Kaufman DL. The frequency of high avidity T cells determines the hierarchy of determinant spreading. J Immunol. 2001;166:7144-7150.
15. Savage PA, Boniface JJ, Davis MM. A kinetic basis for T cell receptor repertoire selection during an immune response. Immunity. 1999;10:485-492.
16. Amrani A, Verdaguer J, Serra P, et al. Progression of autoimmune diabetes driven by avidity maturation of a T-cell population. Nature. 2000;406:739-742.
17. Anderton SM, Radu CG, Lowrey PA, Ward ES, Wraith DC. Negative selection during the peripheral immune response to antigen. J Exp Med. 2001;193:1-11.
18. + T cells with high antigen avidity are prevalent in peripheral blood of patients with type 1 diabetes. Diabetes. 2004;53:1987-1994.
19. Novak EJ, Liu AW, Nepom GT, Kwok WW. MHC class II tetramers identify peptide-specific human CD4(+) T cells proliferating in response to influenza A antigen. J Clin Invest. 1999;104:R63-R67.
20. - T cells. J Clin Invest. 2003;112:1437-1443.
21. Mallone R, Nepom GT. MHC class II tetramers and the pursuit of antigen-specific T cells: define, deviate, delete. Clin Immunol. 2004;110:232-242.
22. Sporri R, Reis e Sousa. Newly activated T cells promote maturation of bystander dendritic cells but not IL-12 production. J Immunol. 2003;171:6406-6413.
23. Reichstetter S, Ettinger RA, Liu AW, et al. Distinct T cell interactions with HLA class II tetramers characterize a spectrum of TCR affinities in the human antigen-specific T cell response. J Immunol. 2000;165:6994-6998.
24. Rocha B, von Boehmer H. Peripheral selection of the T cell repertoire. Science. 1991;251:1225-1228.
25. + T cells. J Exp Med. 1997;185:405-414.
26. + T cells persist in vivo following induction of peripheral tolerance. J Immunol. 1998;160:4719-4729.
27. + lymphocytes by soluble major histocompatibility complex class II-peptide complexes. J Clin Invest. 1994;93:1361-1369.
28. Zhang L, Miller RG, Zhang J. Characterization of apoptosis-resistant antigen-specific T cells in vivo. J Exp Med. 1996;183:2065-2073.
29. Taams LS, van Eden W, Wauben MH. Dose-dependent induction of distinct anergic phenotypes: multiple levels of T cell anergy. J Immunol. 1999;162:1974-1981.
30. + immunoregulatory T cells is antigen nonspecific. J Immunol. 2000;164:183-190.
31. + immunoregulatory cells. J Immunol. 2001;167:1137-1140.
32. + regulatory T cells down-regulate costimulatory molecules on antigen-presenting cells. Eur J Immunol. 2000;30:1538-1543.
33. + T cells. Immunity. 2003;19:877-889.
34. Misra N, Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. Cutting edge: human CD4(+)CD25(+) T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol. 2004;172:4676-4680.
35. Taams LS, van Rensen AJ, Poelen MC, et al. Anergic T cells actively suppress T cell responses via the antigen-presenting cell. Eur J Immunol. 1998;28:2902-2912.
36. Taams LS, Boot EP, van Eden W, Wauben MH. 'Anergic' T cells modulate the T-cell activating capacity of antigen-presenting cells. J Autoimmun. 2000;14:335-341.
37. Vendetti S, Chai JG, Dyson J, et al. Anergic T cells inhibit the antigen-presenting function of dendritic cells. J Immunol. 2000;165:1175-1181.
38. Frasca L, Scotta C, Lombardi G, Piccolella E. Human anergic CD4 T cells can act as suppressor cells by affecting autologous dendritic cell conditioning and survival. J Immunol. 2002;168:1060-1068.
39. - cells. Proc Natl Acad Sci U S A. 2005;102:4103-4108.
40. Khattri R, Kasprowicz D, Cox T, et al. The amount of scurfin protein determines peripheral T cell number and responsiveness. J Immunol. 2001;167:6312-6320.
41. + T cell effector function. J Immunol. 2003;171:1216-1223.
42. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057-1061.
43. + T regulatory cells. Nat Immunol. 2003;4:337-342.
44. + T regulatory cells in humans. Hum Immunol. 2005;66:13-20.
45. Tang Q, Henriksen KJ, Bi M, et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med. 2004;199:1455-1465.
46. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 2002;346:1692-1698.
47. Herold KC, Burton JB, Francois F, et al. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). J Clin Invest. 2003;111:409-418.
48. Belghith M, Bluestone JA, Barriot S, et al. TGFbeta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med. 2003;9:1202-1208.
49. Chatenoud L. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat Rev Immunol. 2003;3:123-132.
50. Appel H, Seth NP, Gauthier L, Wucherpfennig KW. Anergy induction by dimeric TCR ligands. J Immunol. 2001;166:5279-5285.
51. + regulatory T cells in patients with multiple sclerosis. J Exp Med. 2004;199:971-979.
52. + regulatory T cells in autoimmune polyglandular syndrome type II. J Exp Med. 2004;199:1285-1291.
53. Veldman C, Hohne A, Dieckmann D, Schuler G, Hertl M. Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with pemphigus vulgaris. J Immunol. 2004;172:6468-6475.
54. + T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med. 2004;199:1467-1477.
55. Reddy J, Bettelli E, Nicholson L, et al. Detection of autoreactive myelin proteolipid protein 139-151-specific T cells by using MHC II (IAs) tetramers. J Immunol. 2003;170:870-877.